Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects

Trial Profile

A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorecivivint (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Samumed
  • Most Recent Events

    • 13 Nov 2019 Results of pooled analysis from NCT02095548, NCT03122860 and NCT02536833 studies, presented in a Samumed media release.
    • 13 Nov 2019 Accordng to a Samumed media release, safety data pooled from 3 randomized trials NCT02095548, NCT03122860 and NCT02536833 were presented at the 2019 American College of Rheumatology (ACR) Annual Meeting.
    • 15 Nov 2016 Results published in the Samumed Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top